These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17402598)

  • 21. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.
    Thuerauf N; Fromm MF
    Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):281-6. PubMed ID: 16783494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics.
    Staud F; Ceckova M; Micuda S; Pavek P
    Methods Mol Biol; 2010; 596():199-222. PubMed ID: 19949926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The P-glycoprotein transport system and cardiovascular drugs.
    Wessler JD; Grip LT; Mendell J; Giugliano RP
    J Am Coll Cardiol; 2013 Jun; 61(25):2495-502. PubMed ID: 23563132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
    Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
    J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.
    Cascorbi I
    Handb Exp Pharmacol; 2011; (201):261-83. PubMed ID: 21103972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle.
    Aänismaa P; Gatlik-Landwojtowicz E; Seelig A
    Biochemistry; 2008 Sep; 47(38):10197-207. PubMed ID: 18759452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.
    Sakaeda T; Nakamura T; Okumura K
    Pharmacogenomics; 2003 Jul; 4(4):397-410. PubMed ID: 12831320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of genetic polymorphism on the activity of drug transporters and its clinical significance].
    Zhang HX; Wang LS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 33(8):765-9. PubMed ID: 18772522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.
    del Amo EM; Heikkinen AT; Mönkkönen J
    Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-glycoprotein and pharmacokinetics.
    Levêque D; Jehl F
    Anticancer Res; 1995; 15(2):331-6. PubMed ID: 7763002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2.
    Romiti N; Tramonti G; Donati A; Chieli E
    Life Sci; 2004 Dec; 76(3):293-302. PubMed ID: 15531381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.
    Watanabe T; Maeda K; Nakai C; Sugiyama Y
    J Pharm Sci; 2013 Sep; 102(9):3196-204. PubMed ID: 23754337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canalicular transport: discovery of ATP-dependent mechanisms.
    Vore M
    Toxicol Appl Pharmacol; 1993 Jan; 118(1):2-7. PubMed ID: 8094262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
    Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.
    Mealey KL; Waiting D; Raunig DL; Schmidt KR; Nelson FR
    J Vet Pharmacol Ther; 2010 Oct; 33(5):453-60. PubMed ID: 20840389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy versus protein-based therapy: a matter of pharmacokinetics.
    Post MJ; Simons M
    Drug Discov Today; 2001 Aug; 6(15):769-770. PubMed ID: 11470581
    [No Abstract]   [Full Text] [Related]  

  • 39. [The role of changes in the functional activity and the amount of p-glycoprotein in drug pharmacokinetics].
    Ramenskaia GV; Faĭnshteĭn SL; Sychev DA
    Eksp Klin Farmakol; 2007; 70(1):72-80. PubMed ID: 17402598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of P-glycoprotein in pharmacokinetics: clinical implications.
    Lin JH; Yamazaki M
    Clin Pharmacokinet; 2003; 42(1):59-98. PubMed ID: 12489979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.